NASDAQ:AXSM

Axsome Therapeutics (AXSM) Stock Price, News & Analysis

Axsome Therapeutics logo
$134.00 -1.95 (-1.43%)
Closing price 11/18/2026 04:00 PM Eastern
Extended Trading
$133.20 -0.80 (-0.60%)
As of 08:17 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Axsome Therapeutics Stock (NASDAQ:AXSM)

Advanced

Key Stats

Today's Range
$131.56
▼
$136.62
50-Day Range
$129.80
▼
$220.75
52-Week Range
$123.00
▼
$260.19
Volume
743,387 shs
Average Volume
1.14 million shs
Market Capitalization
$7.05 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$266.21
Consensus Rating
Moderate Buy

Company Overview

Axsome Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for central nervous system disorders. The company is headquartered in New York and is led by founder, chairman and chief executive officer Herriot Tabuteau.

Its marketed products include Auvelity, an oral treatment for major depressive disorder in adults, and Sunosi, which is used to improve wakefulness in adults with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea. Axsome also markets Symbravo for the acute treatment of migraine in adults.

Axsome’s commercial activities are primarily focused on the United States. Its research and development pipeline includes potential treatments for other neurological and psychiatric conditions.

AI Generated. May Contain Errors.

Axsome Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
66th Percentile Overall Score

AXSM MarketRank™: 
3.29427083333 of 5 stars

Axsome Therapeutics scored higher than 66% of companies evaluated by MarketBeat, and ranked 410th out of 1,704 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Axsome Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 1 strong buy rating, 17 buy ratings, 2 hold ratings, and 1 sell rating.

  • Upside Potential

    Axsome Therapeutics has a consensus price target of $266.21, representing about 98.7% upside from its current price of $134.00.

  • Amount of Analyst Coverage

    Axsome Therapeutics has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Axsome Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Axsome Therapeutics are expected to grow in the coming year, from ($2.27) to $3.66 per share.

  • Price to Book Value per Share Ratio

    Axsome Therapeutics has a P/B Ratio of 67.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    7.81% of the float of Axsome Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Axsome Therapeutics has a short interest ratio ("days to cover") of 3.35, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Axsome Therapeutics has recently increased by 4.87%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Axsome Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Axsome Therapeutics does not have a long track record of dividend growth.

  • News Sentiment

    Axsome Therapeutics has a news sentiment score of 0.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.38 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 9 news articles for Axsome Therapeutics this week, compared to 7 articles on an average week.
  • Search Interest

    Only 35 people have searched for AXSM on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    Only 6 people have added Axsome Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -14% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Axsome Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,086,500.00 in company stock.

  • Percentage Held by Insiders

    20.60% of the stock of Axsome Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    81.49% of the stock of Axsome Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Axsome Therapeutics' insider trading history.
Receive AXSM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Axsome Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

AXSM Stock News Headlines

A $247 tool for $7
Bill Poulos is offering his $247 Instant Scanner for $7 in the Black Friday sale. It's one payment for a full year, with no re-bills and nothing to install. The catch? He isn't trying to profit on the scanner itself. Poulos is betting that once you see it deliver the night's list, you'll want more of his work for years.tc pixel
What is HC Wainwright's Forecast for AXSM FY2026 Earnings?
See More Headlines

AXSM Stock Analysis - Frequently Asked Questions

Axsome Therapeutics' stock was trading at $182.64 at the beginning of 2026. Since then, AXSM stock has decreased by 26.6% and is now trading at $134.00.

Axsome Therapeutics, Inc. (NASDAQ:AXSM) issued its quarterly earnings results on Monday, November, 2nd. The company reported ($0.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.63) by $0.38. Axsome Therapeutics's quarterly revenue was up 51.9% compared to the same quarter last year.
Read the conference call transcript
.

Axsome Therapeutics (AXSM) raised $52 million in an IPO on Thursday, November 19th 2015. The company issued 4,300,000 shares at a price of $11.00-$13.00 per share. Ladenburg Thalmann and Cantor Fitzgerald & Co. served as the underwriters for the IPO and Brean Capital was co-manager.

Axsome Therapeutics' top institutional shareholders include State Street Corp (1.57%), First Trust Advisors LP (1.05%), Pictet Asset Management Holding SA (0.92%) and Marshall Wace LLP (0.50%). Insiders that own company stock include Roger Jeffs, Nick Pizzie, Mark Coleman, Mark E Saad, Mark L Jacobson, Ari Maizel, Herriot Tabuteau and Hunter R Murdock.
View institutional ownership trends
.

Shares of AXSM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Axsome Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), Tesla (TSLA), Walt Disney (DIS), Palantir Technologies (PLTR) and Vertex Pharmaceuticals (VRTX).

Company Calendar

Last Earnings
11/02/2026
Today
11/19/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:AXSM
CIK
1579428
Employees
925
Year Founded
2012

Price Target and Rating

High Price Target
$380.00
Low Price Target
$205.00
Potential Upside/Downside
+98.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.86
Research Coverage
21 Analysts

Profitability

EPS (Trailing Twelve Months)
($3.06)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$183.17 million
Net Margins
-18.18%
Pretax Margin
-18.10%
Return on Equity
-198.73%
Return on Assets
-22.03%

Debt

Debt-to-Equity Ratio
1.21
Current Ratio
1.42
Quick Ratio
1.34

Sales & Book Value

Annual Sales
$638.50 million
Price / Sales
11.04
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.00 per share
Price / Book
67.00

Miscellaneous

Outstanding Shares
52,600,000
Free Float
41,764,000
Market Cap
$7.05 billion
Optionable
Optionable
Beta
0.86

Social Links

The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

This page (NASDAQ:AXSM) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners